AtriCure (NASDAQ:ATRC) Issues Earnings Results

AtriCure (NASDAQ:ATRC) released its quarterly earnings data on Thursday. The medical device company reported $0.18 earnings per share for the quarter, FiscalAI reports. AtriCure had a positive return on equity of 0.29% and a negative net margin of 0.83%.The company had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. AtriCure updated its FY 2026 guidance to 0.240-0.320 EPS.

Here are the key takeaways from AtriCure’s conference call:

• AtriCure reported Q2 revenue of $154 million, up 13% year over year, with U.S. revenue growth of 14% driven by strong adoption across pain management, appendage management, and open ablation.
• Profitability improved sharply, with adjusted EBITDA of $27.3 million and net income of $9 million; management also raised full-year 2026 adjusted EBITDA guidance to $85 million-$89 million.
• The BoxX-NoAF trial is ahead of schedule, having surpassed 50% enrollment and more than 500 patients, with full enrollment still expected by year-end and data readouts targeted for the first half of 2027.
• Pain management was a standout, growing 27% worldwide on CryoSphere MAX adoption, while CryoXT is still early but expected to contribute more meaningfully in the second half of the year.
• Management acknowledged continued pressure in minimally invasive ablation and some international markets, especially the U.K. and Germany, while noting new competition in appendage management could create near-term trialing but is not expected to derail the business.

AtriCure Stock Down 1.6%

Shares of NASDAQ:ATRC opened at $33.00 on Friday. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -330.00 and a beta of 1.24. AtriCure has a 12-month low of $25.36 and a 12-month high of $43.18. The business has a 50-day moving average price of $29.91 and a 200 day moving average price of $31.40. The company has a current ratio of 4.29, a quick ratio of 3.18 and a debt-to-equity ratio of 0.15.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ATRC. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 4th. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a report on Wednesday, April 1st. Raymond James Financial set a $52.00 target price on shares of AtriCure in a report on Tuesday. Finally, Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $49.12.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 3,000 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total transaction of $85,950.00. Following the completion of the transaction, the director owned 26,373 shares of the company’s stock, valued at $755,586.45. This trade represents a 10.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.00% of the stock is owned by insiders.

Hedge Funds Weigh In On AtriCure

Several large investors have recently made changes to their positions in ATRC. Geneos Wealth Management Inc. acquired a new stake in AtriCure in the 2nd quarter valued at approximately $37,000. Smartleaf Asset Management LLC lifted its stake in AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares in the last quarter. State of Wyoming purchased a new position in shares of AtriCure during the fourth quarter worth $75,000. Kemnay Advisory Services Inc. purchased a new stake in shares of AtriCure in the 4th quarter valued at $114,000. Finally, Strs Ohio acquired a new position in AtriCure during the 1st quarter worth about $158,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure reported Q2 adjusted EPS of $0.18, well above the $0.03 consensus estimate, showing a sharp improvement in profitability versus a year ago. Article Title
• Positive Sentiment: Revenue came in at $153.6 million, ahead of the $151.8 million estimate, indicating continued demand for the company’s surgical AFib and pain-management products. Article Title
• Positive Sentiment: AtriCure raised FY2026 EPS guidance to $0.24-$0.32, far above the $0.12 consensus, which signals management is more confident in the business outlook. Article Title
• Positive Sentiment: Full-year revenue guidance of $602 million-$610 million also slightly tops the street’s $605 million view, supporting expectations for steady growth. Article Title
• Neutral Sentiment: Investors may be watching margin performance closely, since AtriCure still reported a negative net margin, even though profitability improved meaningfully from last year. Article Title

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.